Drug delivery

Doctor administering a vaccine to patient
#Drug delivery #Drug development #Gene therapy #In vivo

Collaboration expands reach in next generation vaccines

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral… Read More

#News

#Cell and gene therapy #Drug delivery #Drug development #Drug innovation #Life sciences

RoslinCT selected as vaccines and advanced therapies training centre

RoslinCT has been confirmed as a National Training Centre, part of the Department for Business, Energy & Industrial Strategy (BEIS) sponsored Advanced Therapies Skills Training Network (ATSTN) initiative. The organisation is the second National Training Centre confirmed as part of the ATSTN initiative, which was set up to develop vaccine… Read More

#News

#Cancer #Cancer research #Drug delivery #Drug innovation #London Cancer Hub #Pharmaceuticals

Global hub for cancer research, treatment and commercial enterprise

Andy Carr, Business Development Manager at The Institute of Cancer Research, London, introduces the new Innovation Gateway at The London Cancer Hub in Sutton, south London, to DDW’s Megan Thomas. MT: I understand the establishment of the Innovation Gateway is underway. What is the progress and when is it due… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #Vaccines

500 million Covid-19 vaccine doses delivered to lowest income countries

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains… Read More

#Covid-19 #News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race to… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News

#Covid-19 #Data #Drug delivery #Drug development #Drug discovery #Research

Interim data suggests drug may prevent cytokine storm

Clinical-stage drug development company Noxopharm has announced that in a cohort of 18 patients with moderately severe cases of Covid-19, interim data from its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with the worsening of the virus. “Until enough people are vaccinated to achieve… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Biotherapeutics #Drug delivery #Drug development #Drug discovery #Research #Therapeutics

Making a difference in allergy and immune disorder treatments

Allergy Therapeutics is a pioneering immunology company, specialised in the research and development of allergy and immune disorder treatments that target the cause, rather than just manage the symptoms. Alan Bullimore, Head of Business Innovation spoke to Lu Rahman about the company’s work and the challenges and opportunities of this… Read More

#Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Drug delivery #Drug development #Drug discovery

Putting the power into drug design: the important role of AI

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Clinical trial #Drug delivery #Drug development #Drug discovery #Gene therapy

Genethon doses first patient in clinical trial of gene therapy for DMD

The first dose of the investigational gene therapy GNT 0004 was given for Dunchenne Muscular Dystrophy (DMD) at I-Motion, the paediatric clinical trial platform for neuromuscular diseases in Paris. The young boy was the first patient in an international phase I/II/III multicentre trial, sponsored by Genethon. The trial has been… Read More

#News

#Biotechnology #CRISPR #Drug delivery #Drug discovery #Genetics / genomics #Pharma

ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 license agreement

ERS Genomics and Nuvisan Innovation Campus Berlin (ICB), an integrated contract research service provider for drug discovery and early development programs, have announced a non-exclusive license agreement granting Nuvisan ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. Nuvisan ICB originated from a spin-out of the major pharma R&D functions of… Read More

#News

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News

#Cancer research #Drug delivery #Drug development #Drug discovery #Research

Karen Vousden wins first Women in Cancer Research award

Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement… Read More

#Cancer Research #News

#Cancer research #DNA #Drug delivery #Drug development #Drug discovery

Blocking a protein may overcome cancer resistance to PARP inhibitors

Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More

#Cancer Research #Editor's Choice #News